Cargando…
Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study
PURPOSE: To evaluate the effect of postoperative adjuvant transarterial chemoembolization (PA-TACE) on the prognosis of hepatocellular carcinoma (HCC) with macroscopic bile duct tumor thrombus (BDTT). PATIENTS AND METHODS: This study included 109 patients who underwent R0 resection for HCC with BDTT...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535114/ https://www.ncbi.nlm.nih.gov/pubmed/33061610 http://dx.doi.org/10.2147/CMAR.S270467 |
_version_ | 1783590416876044288 |
---|---|
author | Huang, Qizhen Lin, Kongying Wang, Lei Zeng, Jianxing Liu, Hongzhi Ding, Zongren Zeng, Yongyi Liu, Jingfeng |
author_facet | Huang, Qizhen Lin, Kongying Wang, Lei Zeng, Jianxing Liu, Hongzhi Ding, Zongren Zeng, Yongyi Liu, Jingfeng |
author_sort | Huang, Qizhen |
collection | PubMed |
description | PURPOSE: To evaluate the effect of postoperative adjuvant transarterial chemoembolization (PA-TACE) on the prognosis of hepatocellular carcinoma (HCC) with macroscopic bile duct tumor thrombus (BDTT). PATIENTS AND METHODS: This study included 109 patients who underwent R0 resection for HCC with BDTT between January 2008 and December 2017: non-TACE (48) and PA-TACE (61). Propensity-score matching (PSM) was conducted in a 1:1 ratio. Recurrence and overall survival (OS) rates were analyzed using the Kaplan–Meier method. Independent risk factors were identified by univariate and multivariate Cox regression analyses. Subgroup analysis was performed by risk-factor stratification. RESULTS: The recurrence rates in the non-TACE and PA-TACE groups were different at 6 months (50.9% vs 26.9%, P=0.03) before PSM and at 6 months (59.3% vs 26.5%, P=0.02) and 12 months (81.4% vs 37.5%, P=0.022) after PSM. OS rates of the non-TACE and PA-TACE groups were different at 6 months (74.0% vs 91.6%, P<0.001) and 12 months (61.1% vs 77.6%, P=0.01) before PSM and at 6 months (73.0% vs 96.8%, P=0.01), 12 months (52.1% vs 89.6%, P=0.001), and 18 months (33.8% vs 64.4%, P=0.034) after PSM. PA-TACE was an independent prognostic factor for both recurrence and OS before and after PSM. Subgroup analysis showed that patients with no HBV infection, tumors >5 cm, macrovascular invasion, alpha-fetoprotein (AFP) >400 ng/mL, or gamma-glutamyl transferase (GGT) >150 U/L benefited significantly from PA-TACE in terms of recurrence rates (all P<0.05). Patients with no HBV infection, multiple tumors, tumors >5 cm, macrovascular invasion, or AFP >400 ng/mL benefited significantly from PA-TACE in terms of OS (all P<0.05). CONCLUSION: PA-TACE could prolong the short-term prognosis of HCC with macroscopic BDTT and should be recommended for patients with no HBV infection, multiple tumors, tumors >5 cm, poor differentiation, macrovascular invasion, AFP >400 ng/mL, or GGT >150 U/L. |
format | Online Article Text |
id | pubmed-7535114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75351142020-10-14 Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study Huang, Qizhen Lin, Kongying Wang, Lei Zeng, Jianxing Liu, Hongzhi Ding, Zongren Zeng, Yongyi Liu, Jingfeng Cancer Manag Res Original Research PURPOSE: To evaluate the effect of postoperative adjuvant transarterial chemoembolization (PA-TACE) on the prognosis of hepatocellular carcinoma (HCC) with macroscopic bile duct tumor thrombus (BDTT). PATIENTS AND METHODS: This study included 109 patients who underwent R0 resection for HCC with BDTT between January 2008 and December 2017: non-TACE (48) and PA-TACE (61). Propensity-score matching (PSM) was conducted in a 1:1 ratio. Recurrence and overall survival (OS) rates were analyzed using the Kaplan–Meier method. Independent risk factors were identified by univariate and multivariate Cox regression analyses. Subgroup analysis was performed by risk-factor stratification. RESULTS: The recurrence rates in the non-TACE and PA-TACE groups were different at 6 months (50.9% vs 26.9%, P=0.03) before PSM and at 6 months (59.3% vs 26.5%, P=0.02) and 12 months (81.4% vs 37.5%, P=0.022) after PSM. OS rates of the non-TACE and PA-TACE groups were different at 6 months (74.0% vs 91.6%, P<0.001) and 12 months (61.1% vs 77.6%, P=0.01) before PSM and at 6 months (73.0% vs 96.8%, P=0.01), 12 months (52.1% vs 89.6%, P=0.001), and 18 months (33.8% vs 64.4%, P=0.034) after PSM. PA-TACE was an independent prognostic factor for both recurrence and OS before and after PSM. Subgroup analysis showed that patients with no HBV infection, tumors >5 cm, macrovascular invasion, alpha-fetoprotein (AFP) >400 ng/mL, or gamma-glutamyl transferase (GGT) >150 U/L benefited significantly from PA-TACE in terms of recurrence rates (all P<0.05). Patients with no HBV infection, multiple tumors, tumors >5 cm, macrovascular invasion, or AFP >400 ng/mL benefited significantly from PA-TACE in terms of OS (all P<0.05). CONCLUSION: PA-TACE could prolong the short-term prognosis of HCC with macroscopic BDTT and should be recommended for patients with no HBV infection, multiple tumors, tumors >5 cm, poor differentiation, macrovascular invasion, AFP >400 ng/mL, or GGT >150 U/L. Dove 2020-09-28 /pmc/articles/PMC7535114/ /pubmed/33061610 http://dx.doi.org/10.2147/CMAR.S270467 Text en © 2020 Huang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Huang, Qizhen Lin, Kongying Wang, Lei Zeng, Jianxing Liu, Hongzhi Ding, Zongren Zeng, Yongyi Liu, Jingfeng Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study |
title | Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study |
title_full | Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study |
title_fullStr | Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study |
title_full_unstemmed | Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study |
title_short | Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study |
title_sort | postoperative adjuvant transarterial chemoembolization improves short-term prognosis of hepatocellular carcinoma with bile duct tumor thrombus: a propensity-score matching study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535114/ https://www.ncbi.nlm.nih.gov/pubmed/33061610 http://dx.doi.org/10.2147/CMAR.S270467 |
work_keys_str_mv | AT huangqizhen postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy AT linkongying postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy AT wanglei postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy AT zengjianxing postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy AT liuhongzhi postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy AT dingzongren postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy AT zengyongyi postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy AT liujingfeng postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy |